Sasaki Eye Clinic, 5-2-6 Mikuni-higashi, Mikuni, Sakai, 913-0016, Japan.
Jpn J Ophthalmol. 2012 May;56(3):214-8. doi: 10.1007/s10384-012-0127-6. Epub 2012 Mar 13.
To report dacryoendoscopic observations and the incidence of lacrimal obstruction/stenosis associated with S-1, an oral anticancer drug.
Retrospective, nonrandomized clinical trial.
A total of 52 patients (41 men, 11 women; age 42-93 years) who were prescribed the anticancer drug S-1 were studied. Patients who suffered eye complaints following S-1 treatment underwent ophthalmic examination, probing and lacrimal irrigation. Patients whose tear meniscus was high or had abnormal lacrimal irrigation were evaluated by dacryoendoscopy.
Overall, 5 of 52 S-1-treated patients (9.6%) experienced lacrimal passage stenosis/obstruction. One patient had punctal stenosis, and four patients had canalicular obstruction/stenosis. The onset of epiphora ranged from 2 to 8 months (4.4 ± 2.2 months, mean ± SD) after the initiation of chemotherapy.
Patients receiving S-1 treatment should be evaluated for potential lacrimal disorders, particularly canalicular obstruction/stenosis. Dacryoendoscopic observation is effective for the diagnosis of this side effect.
报告与 S-1（一种口服抗癌药物）相关的泪道阻塞/狭窄的泪道内镜观察结果和发生率。
回顾性、非随机临床试验。
共研究了 52 名接受抗癌药物 S-1 治疗的患者（41 名男性，11 名女性；年龄 42-93 岁）。在 S-1 治疗后出现眼部不适的患者接受了眼科检查、探通和泪道冲洗。泪液新月高或泪道冲洗异常的患者进行泪道内镜检查。
52 名接受 S-1 治疗的患者中（9.6%），共有 5 名（9.6%）出现泪道狭窄/阻塞。1 名患者存在泪小点狭窄，4 名患者存在泪小管阻塞/狭窄。溢泪的发病时间为化疗开始后 2 至 8 个月（4.4±2.2 个月，平均值±标准差）。
接受 S-1 治疗的患者应评估潜在的泪器疾病，尤其是泪小管阻塞/狭窄。泪道内镜观察对该副作用的诊断有效。
